News

The product candidates are currently in early- to mid-stage clinical development for a variety of diseases. They target several novel pathways of disease by inhibiting the activity of

Sage Healthcare Division, which serves more than 400,000 healthcare professionals, including 80,000 physicians in North America, will make its ONC-ATCB certified Sage Intergy Meaningful Use Edition available to

Spectrum Pharma’s Fusilev injection has been approved as the rescue after high-dose methotrexate therapy in osteosarcoma. Fusilev is also indicated to diminish the toxicity and counteract the effects

Daiichi Sankyo is developing Edoxaban for several other indications which include stroke prevention in atrial fibrillation (AF) patients, and treatment and prevention of recurrent venous thromboembolism. Further, Daiichi

Merck Capital Ventures (MCV), the venture capital arm of Merck and one of ImpactRx’s existing investors, will maintain its investment in ImpactRx. Under the terms of the acquisition

IMO-2125 is a novel immune modulator being developed as a component of treatment for chronic hepatitis C virus (HCV) infection. IMO-2125 has been evaluated in 96 HCV-infected patients

The vaccines division of the Sanofi-aventis Group, Sanofi Pasteur said the FDA’s decision was supported by the results from one Phase II and three Phase III multicenter trials,

InfoGard is approved by the Office of the National Coordinator for Health Information Technology (ONC) of the US Department of Health and Human Services (HHS) as an Authorized

Japanese approval was given on the basis a pivotal Phase III Embrace (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) study results and a Phase II